Asieris(SH:688176) Zhong Guo Jing Ji Wang·2025-03-20 02:42Core Points - The company reported a significant increase in revenue for 2024, achieving 201.62 million yuan, a year-on-year growth of 1,366.01% [1] - The net profit attributable to the parent company was -387.68 million yuan, an improvement from -400.43 million yuan in the previous year [1] - The company has experienced net losses over the years, with figures showing a consistent decline in profitability since 2018 [1] Financial Performance - In 2024, the company achieved operating revenue of 201.62 million yuan, marking a substantial increase compared to previous years [1] - The net profit attributable to the parent company for 2024 was -387.68 million yuan, compared to -400.43 million yuan in 2023 [1] - The net profit excluding non-recurring gains and losses was -412.86 million yuan for 2024, an improvement from -432.22 million yuan in the previous year [1] - Historical net losses from 2018 to 2023 show a trend of increasing deficits, with the most recent figures indicating a net loss of -400 million yuan in 2023 [1] Stock Market Performance - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 7, 2022, with an initial offering of 110 million shares at a price of 22.98 yuan per share [2] - The stock price fell below the offering price on the first day of trading, reaching a maximum of 20.00 yuan [2] - Currently, the stock remains in a state of decline, having not recovered from its initial drop [3] Fundraising and Use of Proceeds - The total amount raised from the initial public offering was 2.528 billion yuan, with a net amount of 2.381 billion yuan after deducting issuance costs [4] - The final net amount raised exceeded the original plan by 311 million yuan, which was initially set at 2.070 billion yuan [5] - The funds are intended for projects related to pharmaceuticals, medical devices, new drug development, marketing network construction, and working capital [5]